A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Oral HRS-5346 in Adult Patients at High Risk of Cardiovascular Events With Elevated Lipoprotein(a)
Latest Information Update: 04 Mar 2025
Price :
$35 *
At a glance
- Drugs HRS 5346 (Primary)
- Indications Metabolic disorders
- Focus Adverse reactions
- Sponsors Shandong Suncadia Medicine
- 25 Feb 2025 Status changed from not yet recruiting to recruiting.
- 13 Feb 2025 New trial record